PTEN and Cancer
Alternative Lengthening of Telomeres Renders Cancer Cells Hypersensitive to ATR Inhibitors
Molecular Classification of Endometrial Cancer and Targeted Therapy Considerations
Prognosis and Potential: How POLE and PIK3R1 Are Changing How We Approach Endometrial Cancer
Homologous Recombination Deficient Diagnosis and PARP Inhibitor Therapy | Webinar | Ambry Genetics
Study of DNA Repair Pathways for Improving Therapeutic Gain in Cancer: A Systems Biology Approach
Unveiling Potential of DNA Polymerase III Inhibitors to Limit Helicobacter pylori
Topoisomerase 1 and 2
PAY ATTENTION TO THE PASSENGER: A new therapeutic target in cancer cell DNA
Using CRISPR-Cas9 screens to study DNA repair: Function of Ape2 in alternative end-joining
Emerging Immunotherapies & Novel Therapeutics in Endometrial Cancer Symposium
#IDIBELLconnect: Understanding the cancer-predisposing syndrome caused by defective POLE and POLD1.
DNA Replication (Updated)
【演講】EP02｜English Ver.｜Allosteric Inhibition mechanism of TCIs on the Viral NPexo｜Prof. Yu-Yuan Hsiao
Panel Presentation: HRD Evaluation and Scoring Using OncoScan CNV Assay, a Whole-Genome Micro...
CSHL Keynote, Dr. Lee Zou, MGH Cancer Center/Harvard Medical School
Dr. Polina Shcherbakova October 10th 2023
Genomic instability
Navigating New Waters for Advanced or Recurrent Endometrial Cancer
